Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of Alabama at Birmingham: Clinical Trials & FDA Approval Profile

University of Alabama at Birmingham (Global / Institutional) sponsors 100 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 45 active protocols (28 recruiting now), 25 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)30.0%
Median Closed Enrollment vs National (145 pts)36 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of Alabama at Birmingham
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)100
Active Pipeline (Recruiting Now)45 (28)
Completed vs Stopped Early25 / 30 (30.0%)
Median Closed Actual Enrollment36 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University of Alabama at Birmingham
Hospital Research SiteLocationShared Protocols
University of Alabama at BirminghamBirmingham, AL57
Mayo Clinic RochesterRochester, MN6
Oregon Health and Science University Knight Cancer InstitutePortland, OR6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by University of Alabama at Birmingham
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05026749Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in ChildrenPhase IIIRECRUITING
NCT06188741Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1Phase IIRECRUITING
NCT04692493RA-PRO PRAGMATIC TRIALPhase IIIRECRUITING
NCT05231629Sequential Therapy in Multiple Myeloma Guided by MRD AssessmentsPhase IIACTIVE NOT RECRUITING
NCT05143840Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhasePhase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the University of Alabama at Birmingham Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI